Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial
Abstract Background Third‑generation CAR-T cells demonstrated promising efficacy and remarkably low toxicity in refractory or relapsed (R/R) B-cell malignancies. However, data on the patients with central nervous system (CNS) involvement are limited due to concerns regarding treatment-related neurot...
Saved in:
| Main Authors: | Bailin He, Ren Lin, Na Xu, Le Qin, Zhixiang Wang, Qiang Wang, Xiaofang Li, Xiaolei Wei, Yongqiang Wei, Zhaoyang Tang, Zhiping Fan, Fen Huang, Xiaoli Liu, Jing Sun, Li Xuan, Peng Li, Hongsheng Zhou, Qifa Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-025-06608-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case report of non-gene editing CD7 CAR T cell therapy in CD7+ Sézary syndrome: preclinical validation and first-in-human use
by: Haichan Xu, et al.
Published: (2025-08-01) -
TET2 downregulation enhances the antitumor efficacy of CD19 CAR T cells in a preclinical model
by: Yeongrin Kim, et al.
Published: (2025-02-01) -
Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma
by: Yuejiao Huang, et al.
Published: (2025-05-01) -
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity
by: Sara Caratelli, et al.
Published: (2025-02-01) -
Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways
by: Bailin He, et al.
Published: (2025-04-01)